Myokardia Inc (NASDAQ:MYOK) CEO Anastasios Gianakakos sold 5,000 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $65.02, for a total value of $325,100.00. Following the sale, the chief executive officer now owns 90,864 shares in the company, valued at $5,907,977.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Anastasios Gianakakos also recently made the following trade(s):
- On Monday, November 4th, Anastasios Gianakakos sold 5,000 shares of Myokardia stock. The stock was sold at an average price of $59.07, for a total value of $295,350.00.
- On Wednesday, October 2nd, Anastasios Gianakakos sold 4,000 shares of Myokardia stock. The stock was sold at an average price of $52.28, for a total transaction of $209,120.00.
- On Wednesday, September 11th, Anastasios Gianakakos sold 1,000 shares of Myokardia stock. The stock was sold at an average price of $55.00, for a total transaction of $55,000.00.
NASDAQ:MYOK traded up $0.19 during mid-day trading on Thursday, reaching $68.02. 843 shares of the stock were exchanged, compared to its average volume of 419,891. Myokardia Inc has a 1-year low of $39.01 and a 1-year high of $68.60. The firm has a market capitalization of $3.08 billion, a PE ratio of -38.33 and a beta of 2.07. The business has a fifty day moving average price of $61.68 and a 200 day moving average price of $54.74.
Myokardia (NASDAQ:MYOK) last posted its quarterly earnings data on Monday, November 11th. The biotechnology company reported ($1.34) EPS for the quarter, beating analysts’ consensus estimates of ($1.91) by $0.57. As a group, research analysts expect that Myokardia Inc will post -4.6 earnings per share for the current year.
A number of large investors have recently added to or reduced their stakes in the stock. TD Asset Management Inc. boosted its holdings in Myokardia by 0.8% in the 2nd quarter. TD Asset Management Inc. now owns 63,582 shares of the biotechnology company’s stock valued at $3,188,000 after purchasing an additional 500 shares during the period. Los Angeles Capital Management & Equity Research Inc. raised its holdings in shares of Myokardia by 2.9% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 17,965 shares of the biotechnology company’s stock worth $901,000 after buying an additional 510 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Myokardia by 20.7% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,382 shares of the biotechnology company’s stock worth $176,000 after buying an additional 579 shares in the last quarter. First Trust Advisors LP lifted its position in shares of Myokardia by 4.4% during the 2nd quarter. First Trust Advisors LP now owns 15,116 shares of the biotechnology company’s stock worth $758,000 after buying an additional 642 shares during the period. Finally, Quadrant Capital Group LLC bought a new position in shares of Myokardia during the 3rd quarter worth approximately $33,000.
Several equities analysts recently commented on MYOK shares. BidaskClub raised Myokardia from a “hold” rating to a “buy” rating in a research report on Saturday, November 30th. Cowen reaffirmed a “buy” rating and set a $73.00 price target on shares of Myokardia in a research note on Monday, November 11th. ValuEngine lowered Myokardia from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 3rd. Morgan Stanley increased their price target on Myokardia from $70.00 to $75.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, Maxim Group reissued an “average” rating on shares of Myokardia in a report on Monday, October 28th. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $77.33.
Myokardia Company Profile
MyoKardia, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM.
Receive News & Ratings for Myokardia Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Myokardia and related companies with MarketBeat.com’s FREE daily email newsletter.